Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Envista makes dental products—from implants and braces to the tools and machines dentists use every day—and sells them to dentists, orthodontists, and dental labs around the world.
Envista is a pure-play dental company, a collection of brands that together cover a surprising amount of what happens in a dental office. If you've ever had a cavity filled, a tooth replaced, or braces put on, there's a decent chance one of Envista's products was involved somewhere. Its equipment and consumables business sells things like imaging systems, handpieces, and infection-control supplies, while its specialty arm sells implants and orthodontic products, including clear aligners.
The company was spun off from Danaher in 2019. Danaher had assembled a portfolio of dental businesses over the years, and Envista was carved out to focus solely on dentistry. That spin-off is a useful lens for understanding the business: Danaher kept the faster-growing, higher-margin life sciences and diagnostics operations, while Envista took the dental assets, which are steadier and more tied to routine patient visits. Envista's brands include Nobel Biocare (implants), Ormco (orthodontics), and KaVo and DEXIS (equipment and imaging), and it sells in over a hundred countries. The core economics are recurring. Dentists who buy an implant system or an imaging machine tend to keep buying the consumables and accessories that go with it, which gives Envista a stream of repeat revenue on top of big-ticket equipment sales. That said, the business faces real pressure: it competes with larger rivals like Straumann in implants and Align Technology in clear aligners, and it has been restructuring under a new CEO to simplify operations and improve margins after a stretch of disappointing results. In 2023 it also disclosed an accounting issue tied to its KaVo subsidiary that hit its stock and led to a restatement, a reminder that carve-outs don't always run smoothly.
Envista is a bet on something simple: aging populations and rising middle classes mean more people getting dental care over time. The company doesn't sell to consumers directly—it sells to the dentists and labs who do the work—so its fortunes depend on procedure volumes and whether dentists choose its brands. It pays no meaningful dividend and has focused on paying down debt from the spin-off and investing in its brands, making it a steady, cyclical business rather than a fast grower.
Saved answer · last researched 5 Nov 2026